Shearman & Sterling advised Jacobson Pharma Corporation Limited on its global offering and initial public offering on the Main Board of The Stock Exchange of Hong Kong Limited. BOCI Asia Limited acted as the sole sponsor, sole global coordinator, sole bookrunner and sole lead manager.

Jacobson Pharma is the largest generic drug company in Hong Kong with more than 30 percent share of the total generic drug market since 2012.

The Shearman & Sterling team was led by partner Colin Law (Hong Kong-Capital Markets); with support from counsel Edward Bong (Hong Kong-Capital Markets); and associates Clement Jiang, Marshall Chu, Steven Wu (Hong Kong-Capital Markets) and Stella Hu (Beijing-Capital Markets).